Jefferies Maintains Bausch Health(BHC.US) With Buy Rating, Cuts Target Price to $9
Bausch Health Companies Inc. Price Target Cut to $9.00/Share From $13.00 by Jefferies & Co
TD Cowen Maintains Bausch Health(BHC.US) With Hold Rating, Maintains Target Price $12
Bausch Health: A Balanced Hold Amid Revenue Growth and Operational Challenges
Bausch Health Companies Inc. Price Target Cut to $8.50/Share From $10.00 by Scotiabank
A Quick Look at Today's Ratings for Bausch Health(BHC.US), With a Forecast Between $3 to $8.5
Bausch Health Companies Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Neurocrine (NBIX)
Jefferies Maintains Bausch Health(BHC.US) With Buy Rating, Cuts Target Price to $13
Bausch Health Companies Analyst Ratings
Truist Financial Maintains Bausch Health(BHC.US) With Hold Rating, Maintains Target Price $8
Truist Financial Maintains Bausch Health(BHC.US) With Hold Rating, Announces Target Price $8
Bausch Health Companies: Hold Rating Amid Bankruptcy Rumors and Financial Uncertainties
RBC Capital Maintains Bausch Health(BHC.US) With Hold Rating, Maintains Target Price $10
Bausch Health Companies Analyst Ratings
Morgan Stanley Upgrades Bausch + Lomb, Cites Improving Margins
Truist Financial Reaffirms Their Hold Rating on Bausch Health Companies (BHC)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)
Piper Sandler Reaffirms Their Hold Rating on Bausch Health Companies (BHC)
Royal Bank of Canada: Maintaining the Bausch Health Companies (BHC.US) rating, adjusted from being equal to the general market to being equal to the general market, and the target price was adjusted from $12.00 to $11.00.